Dr. Gille is a physician scientist with significant subject matter expertise in cardiovascular and metabolic disease drug development.  He is a Fellow of the American Heart Association, and brings >15 years of pharmaceutical industry experience to Abcentra.  He previously led translational strategy for cardiovascular drug development programs at Sanofi and CSL Behring.  While he was at CSL, he led the CSL-112 program’s translational strategy, a cholesterol-effluxing drug that CSL was developing for ACS and took into a CV outcomes trial called AEGIS-II.

He is now tasked with leading Abcentra’s translational and pharmacology strategy, a critical pillar of the our phase 2b program, as we prepare orticumab for phase 3.